A Phase 2 interventional study of SBRT in Plasmacytoma, sponsored by Instituto do Cancer do Estado de São Paulo. Terminated at 1 site in Brazil. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-04-06.
Sponsored by Instituto do Cancer do Estado de São Paulo · Phase 2, Interventional, and Treatment
This project aims to propose a new approach in the treatment of solitary plasmacytoma: hypofractionated irradiation alone with stereotactic technique that may contribute to the successful treatment of this disease.
This work aims to apply this new technique with the primary objective of reducing the progression-free survival for multiple myeloma of patients treated for solitary plasmacytoma, as well as quantify overall survival, local control, toxicities and quality of life in a phase I trial / II.
Solitary plasmacytoma is a rare disease whose treatment has not evolved much in the last decades. The role of radiotherapy in the curative treatment of this entity was defined in a major publication in the 1980s and has since been proven to be the best practice in several other comparative trials, mostly retrospective. The radiotherapy dose of curative intent has also been described over the same period and remains unchanged to this day. Thus, local control, disease cure rate, and rate and progression time for multiple myeloma have been unaffected for almost 30 years.
Radiobiology of plasmacytoma cells is also not widely studied. The alpha / beta ratio, which defines the pattern of response of this disease to radiotherapy fractions and its response time, is also not well described. However, it is believed to be smaller in comparison to other hematological malignancies due to reports of cases of intrinsic radioresistance and late recurrence and reports of success with hypofractionated dose in isolated cases where stereotactic techniques were used such as base of skull and spine.
Exclusion Criteria:
Prospective arm with patients being treated with SBRT
Radiation: SBRT
Stereotactic Body Radiotherapy
Progression-free survival for multiple myeloma
Progression-free survival for multiple myeloma at 5 years evaluation in patients undergoing SBRT for solitary plasmacytoma compared to a retrospective cohort of patients
Time frame: 5 years
Local control rate
Local progression-free survival
Time frame: 5 years
Overall survival
Overall survival
Time frame: 5 years
Survival free of bone events
Those are described as fractures, osteomyelitis, necessity of surgery, deformation of bone or ironic bone pain
Time frame: 5 Years
Toxicities
Toxicities in the scale of common criteria of toxicity by the National Cancer Institute CTCAE v4
Time frame: 5 Years
Quality of Life
Quality of life of patients in the prospective cohort using the EORTC QLQ-30 questionnaire
Time frame: 5 years
Quality of Life
Quality of life of patients in the prospective cohort using the Short Form Health Survey 36 v.2 (SF-36) questionnaire
Time frame: 5 years
Dosimetric prognostic factors
Describe and explore dosimetric factors for local control and toxicities
Time frame: 5 years
Plan to share: No
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto do Cancer do Estado de São Paulo